LianBio (LIANY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LianBio (LIANY) trades at $0.14 with AI Score 51/100 (Hold). LianBio is a biopharmaceutical company focused on developing and commercializing innovative medicines in China and other Asian markets. Market cap: 16M, Sector: Healthcare.
Last analyzed: Mar 15, 2026LianBio (LIANY) Healthcare & Pipeline Overview
LianBio is a biopharmaceutical company focused on licensing and developing therapeutics for cardiovascular, oncology, ophthalmology, and inflammatory diseases in China and other Asian markets, facing the challenges of regulatory hurdles and market access while offering a high dividend yield of 260.61% and operating with a beta of 0.42.
Investment Thesis
LianBio presents a high-risk, high-reward investment opportunity. The company's strategy of in-licensing and developing drugs for the Chinese and Asian markets offers significant potential, given the large patient populations and unmet medical needs. Key value drivers include successful clinical trials and regulatory approvals for its pipeline assets, particularly mavacamten, TP-03, and NBTXR3. The company's current P/E ratio is 7.21, and the dividend yield is 260.61%. However, investors should be aware of the risks associated with drug development, regulatory hurdles, and market access in China. The company's relatively small market cap of $0.02 billion also introduces volatility. Upcoming clinical trial results and regulatory decisions will be critical catalysts for the stock.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.02 billion indicates a small-cap company with potential for high growth but also higher volatility.
- P/E ratio of 7.21 suggests the company may be undervalued compared to its earnings, but this should be considered in the context of its growth stage and risks.
- Dividend yield of 260.61% is exceptionally high and may not be sustainable, warranting further investigation into the company's financial stability and dividend policy.
- Beta of 0.42 indicates the stock is less volatile than the market, which may appeal to risk-averse investors.
- Focus on the Chinese and Asian markets provides access to large patient populations and potential for significant revenue growth if key drugs are approved and commercialized successfully.
Competitors & Peers
Strengths
- Strong pipeline of drug candidates targeting multiple therapeutic areas.
- Strategic partnerships with international pharmaceutical companies.
- Focus on the high-growth Chinese and Asian pharmaceutical markets.
- Experienced management team with expertise in clinical development and regulatory affairs.
Weaknesses
- Reliance on in-licensing drug candidates, which can be subject to availability and competition.
- High R&D costs and long development timelines associated with drug development.
- Regulatory hurdles and market access challenges in China and other Asian countries.
- Small market capitalization and limited financial resources compared to larger pharmaceutical companies.
Catalysts
- Upcoming: Clinical trial results for Mavacamten in hypertrophic cardiomyopathy.
- Upcoming: Regulatory approval decisions for TP-03 in Demodex blepharitis.
- Upcoming: Clinical trial data releases for NBTXR3 in head and neck squamous cell carcinoma.
- Ongoing: Expansion of partnerships to broaden the pipeline of drug candidates.
- Ongoing: Advancements in regulatory reforms in China to accelerate drug approvals.
Risks
- Potential: Unsuccessful clinical trials for key drug candidates.
- Potential: Regulatory setbacks or delays in drug approvals in China and other Asian countries.
- Potential: Competition from larger pharmaceutical companies with greater resources.
- Ongoing: High R&D costs and long development timelines associated with drug development.
- Ongoing: Dependence on in-licensing drug candidates, which can be subject to availability and competition.
Growth Opportunities
- Expansion of Mavacamten: Mavacamten, targeting obstructive and non-obstructive hypertrophic cardiomyopathy, represents a significant growth opportunity. The global market for heart failure therapeutics is projected to reach $16.5 billion by 2028. Successful clinical trials and regulatory approval in China could drive substantial revenue growth for LianBio. The timeline for approval is dependent on ongoing trials and regulatory review processes.
- Commercialization of TP-03: TP-03, for the treatment of Demodex blepharitis, offers a targeted growth opportunity in the ophthalmology space. The global blepharitis market is expected to reach $640 million by 2027. LianBio's partnership with Tarsus Pharmaceuticals provides a strong foundation for commercialization in China. Regulatory approval and successful market penetration are key to realizing this growth potential.
- Development of NBTXR3: NBTXR3, a radioenhancer for head and neck squamous cell carcinoma and solid tumors, presents a significant growth opportunity in oncology. The global market for cancer therapeutics is projected to reach $286 billion by 2025. Successful clinical trials and regulatory approval could position NBTXR3 as a valuable addition to cancer treatment regimens. LianBio's partnership with Nanobiotix S.A. is crucial for this development.
- Advancement of Infigratinib: Infigratinib, targeting cholangiocarcinoma and gastric cancers, represents a strategic growth opportunity in oncology. The global market for cholangiocarcinoma therapeutics is growing due to increasing incidence rates. Successful clinical trials and regulatory approval in China could drive significant revenue growth for LianBio. The timeline for approval is dependent on ongoing trials and regulatory review processes.
- Pipeline Expansion: LianBio's pipeline of other drugs, including BBP-398, Omilancor, NX-13, LYR-210 and Sisunatovir, provides multiple avenues for future growth. Each of these drugs targets specific unmet medical needs in large patient populations. Successful clinical development and regulatory approval could contribute significantly to LianBio's long-term growth prospects. The timeline for approval is dependent on ongoing trials and regulatory review processes.
Opportunities
- Expanding their pipeline through additional in-licensing agreements.
- Accelerating the development and approval of their existing drug candidates.
- Expanding their geographic reach within China and other Asian markets.
- Leveraging their expertise to develop novel drug candidates in-house.
Threats
- Competition from larger pharmaceutical companies with greater resources.
- Unsuccessful clinical trials or regulatory setbacks for their drug candidates.
- Changes in regulatory policies or market conditions in China and other Asian countries.
- Intellectual property disputes or challenges to their patent protection.
Competitive Advantages
- Strategic partnerships with international pharmaceutical companies provide access to innovative drug candidates.
- Focus on the Chinese and Asian markets allows them to address specific unmet medical needs in these regions.
- Expertise in clinical development and regulatory affairs helps them navigate the complex drug approval process.
- Diversified pipeline of drug candidates targeting multiple therapeutic areas reduces reliance on any single product.
About LIANY
LianBio, incorporated in 2019 and headquartered in Princeton, New Jersey, is a biopharmaceutical company dedicated to bringing innovative medicines to patients in China and other Asian markets. The company focuses on in-licensing and developing therapies for significant unmet medical needs across cardiovascular, oncology, ophthalmology, and inflammatory diseases. LianBio's pipeline includes mavacamten for hypertrophic cardiomyopathy and heart failure, TP-03 for Demodex blepharitis and meibomian gland disease, NBTXR3 for head and neck squamous cell carcinoma and solid tumors, Infigratinib for cholangiocarcinoma and gastric cancers, BBP-398 for solid tumors, Omilancor and NX-13 for ulcerative colitis and Crohn's disease, LYR-210 for chronic rhinosinusitis, and Sisunatovir for respiratory syncytial virus. LianBio has established strategic partnerships with companies like Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 and Nanobiotix S.A. to develop and commercialize NBTXR3. The company aims to address critical healthcare needs in its target markets by leveraging its expertise in clinical development and regulatory affairs.
What They Do
- Develop and commercialize medicines for cardiovascular diseases.
- Focus on oncology therapeutics for various types of cancers.
- Address ophthalmological conditions like Demodex blepharitis.
- Develop treatments for inflammatory diseases such as ulcerative colitis and Crohn's disease.
- Target the Chinese and other Asian pharmaceutical markets.
- Partner with international pharmaceutical companies to in-license drug candidates.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
Business Model
- In-licensing drug candidates from other pharmaceutical companies.
- Developing and conducting clinical trials for these drug candidates.
- Seeking regulatory approval for their drugs in China and other Asian markets.
- Commercializing and marketing their approved drugs in these markets.
Industry Context
LianBio operates in the competitive biotechnology industry, characterized by high R&D costs, lengthy development timelines, and regulatory scrutiny. The company focuses on the Chinese and Asian markets, which are experiencing rapid growth in healthcare spending and demand for innovative medicines. Key trends include increasing regulatory reforms to accelerate drug approvals and growing investment in local biotech companies. LianBio competes with both multinational pharmaceutical companies and local Chinese players. Competitors include companies like CHMMF and CUBT, which are also developing and marketing pharmaceutical products.
Key Customers
- Patients in China and other Asian countries suffering from cardiovascular diseases.
- Patients with various types of cancer, including cholangiocarcinoma and gastric cancers.
- Individuals suffering from ophthalmological conditions like Demodex blepharitis.
- Patients with inflammatory diseases such as ulcerative colitis and Crohn's disease.
Financials
Chart & Info
LianBio (LIANY) stock price: $0.14 (-0.04, -20.81%)
Latest News
No recent news available for LIANY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LIANY.
Price Targets
Wall Street price target analysis for LIANY.
MoonshotScore
What does this score mean?
The MoonshotScore rates LIANY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Adam Leo Stone
CEO
Adam Leo Stone serves as the CEO of LianBio, leading the company's efforts to develop and commercialize innovative medicines in China and other Asian markets. His background includes extensive experience in the pharmaceutical industry, with a focus on business development, strategic planning, and commercial operations. He has held leadership positions at various pharmaceutical companies, contributing to the successful launch and growth of several key products. Stone's expertise spans multiple therapeutic areas, including oncology, cardiovascular, and inflammatory diseases.
Track Record: Under Adam Leo Stone's leadership, LianBio has focused on building a robust pipeline of drug candidates through strategic in-licensing agreements and partnerships. He has overseen the advancement of key programs through clinical development and regulatory review. Stone has also been instrumental in establishing LianBio's presence in the Chinese and Asian markets, navigating the complex regulatory landscape and building relationships with key stakeholders. The company manages 163 employees under his leadership.
LIANY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that LianBio may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier is distinct from trading on major exchanges like the NYSE or NASDAQ, which have stricter listing requirements and greater regulatory oversight. This lower tier designation signals a higher degree of risk and requires increased due diligence from potential investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in LianBio.
- Low liquidity can make it difficult to buy or sell shares.
- Higher potential for price manipulation due to the lack of regulatory oversight.
- OTC Other tier stocks are generally more volatile than those listed on major exchanges.
- The company may not meet the minimum financial standards of higher-tier exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Monitor the company's news releases and public disclosures.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company is incorporated in 2019 and headquartered in Princeton, New Jersey.
- LianBio has strategic partnerships with established pharmaceutical companies like Tarsus Pharmaceuticals and Nanobiotix S.A.
- The company has a diversified pipeline of drug candidates targeting multiple therapeutic areas.
LianBio Stock: Key Questions Answered
What does LianBio do?
LianBio is a biopharmaceutical company focused on identifying, developing, and commercializing innovative medicines for unmet medical needs in China and other Asian markets. The company in-licenses promising drug candidates from Western pharmaceutical companies and advances them through clinical development and regulatory approval in its target markets. LianBio's pipeline targets cardiovascular, oncology, ophthalmology, and inflammatory diseases, leveraging strategic partnerships to bring novel therapies to patients in Asia.
What do analysts say about LIANY stock?
Analyst coverage of LIANY stock is limited due to its small market capitalization and OTC listing. Key valuation metrics, such as P/E ratio and dividend yield, should be interpreted cautiously given the company's growth stage and inherent risks. Growth considerations include successful clinical trial outcomes, regulatory approvals, and market penetration in China and other Asian countries. Analyst consensus is not readily available, and investors should conduct their own thorough research before making investment decisions. No buy/sell recommendations are available.
What are the main risks for LIANY?
The main risks for LianBio include the inherent uncertainties of drug development, such as unsuccessful clinical trials and regulatory setbacks. The company also faces competition from larger pharmaceutical companies and challenges associated with market access in China and other Asian countries. Dependence on in-licensing drug candidates exposes LianBio to the risk of losing access to key assets. The company's OTC listing and small market capitalization contribute to increased volatility and liquidity risks. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for LIANY?
LianBio (LIANY) currently holds an AI score of 51/100, indicating moderate score. The stock trades at a P/E of 6.1x, below the S&P 500 average (~20-25x), potentially signaling value. Key strength: Strong pipeline of drug candidates targeting multiple therapeutic areas.. Primary risk to monitor: Potential: Unsuccessful clinical trials for key drug candidates.. This is not financial advice.
How frequently does LIANY data refresh on this page?
LIANY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LIANY's recent stock price performance?
Recent price movement in LianBio (LIANY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong pipeline of drug candidates targeting multiple therapeutic areas.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LIANY overvalued or undervalued right now?
Determining whether LianBio (LIANY) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 6.1. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LIANY?
Before investing in LianBio (LIANY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.